SCHEMBL6732039

SCHEMBL6732039

CS(=O)(=O)c1ccc(Br)c(F)c1F

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.36
KDM1A O60341 2/20 0.34
KCNH2 Q12809 2/20 0.34
KDM1B Q8NB78 2/20 0.34
CCR2 P41597 4/20 0.34
PTGS2 P35354 2/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
EPAS1 Q99814 2/20 0.30
ALOX5AP P20292 1/20 0.30
FEN1 P39748 1/20 0.30
PTGS1 P23219 1/20 0.30
PLCG1 P19174 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2776078 0.82 CA2 (0.46) KDM1AKCNH2KDM1BCA1CA2
SCHEMBL29843398 0.82 CA2 (0.46) KDM1AKCNH2KDM1BCA1CA2
SCHEMBL31001623 0.81 CCR2 (0.38) L3MBTL1CCR2PTGS2CA1CA2
SCHEMBL8176124 0.81 CCR2 (0.38) L3MBTL1CCR2PTGS2CA1CA2
SCHEMBL6736791 0.80 TRPV4 (0.36) KDM1AKCNH2KDM1BCA1CA2
SCHEMBL30291227 0.80 TRPV4 (0.36) KDM1AKCNH2KDM1BCA1CA2
SCHEMBL12560651 0.79 LMNA (0.44) L3MBTL1CCR2PTGS2ALDH1A1
SCHEMBL12468302 0.78 CCR2 (0.39) L3MBTL1CCR2PTGS2
SCHEMBL26298434 0.77 L3MBTL1 (0.45) L3MBTL1CCR2PTGS2ALDH1A1EPAS1
SCHEMBL20226659 0.76 L3MBTL1 (0.44) L3MBTL1CCR2PTGS2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 L3MBTL1 1836/4885KDM1A 1683/4885KCNH2 4119/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 L3MBTL1 1836/4885KDM1A 1683/4885KCNH2 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.